Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type ...( PARIS September 10 /- - Abstra...)

PARIS, September 10 /PRNewswire-FirstCall/ --

- Abstracts 185 and 1112

Sanofi-aventis, a world leader in diabetes care, announced results from two randomized clinical studies presented at the European Association for the Study of Diabetes (EASD) 44th Annual Meeting demonstrating that the "basal plus" insulin strategy with LANTUS(R) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and APIDRA(R) once daily (prandial insulin) (insulin glulisine (rDNA origin) injection) administered at the main meal (defined by the highest postprandial blood glucose level) improve blood glucose levels in patients with type 2 diabetes after basal insulin optimisation.

In the ELEONOR (Optimising basal plus insulin therapy in type 2 diabetes by telecare assistance for self-monitoring of blood glucose) and OPAL (Adding a single dose of insulin glulisine at breakfast or main meal to basal insulin and oral antidiabetic therapy) clinical studies, patients previously treated with LANTUS(R) and oral diabetes medications achieved significantly improved glycaemic control by implementing a "basal plus" regimen - adding one injection of APIDRA(R) at the main meal of the day. In the ELEONOR study, the addition of one APIDRA(R) injection resulted in a further A1C drop of 0.7-0.8%. In the OPAL study, A1C scores improved, significantly dropping 0.4% from baseline to endpoint in both patients that were administered APIDRA(R) at breakfast and patients who were administered APIDRA(R) at main meal.

"With so many people living with diabetes not reaching their A1C goals, we're always looking for new ways to help manage blood glucose levels," said Dr. Del Prato, Professor of Endocrinology and Metabolism and Chief of the Section of Diabetes at the School of Medicine, University of Pisa, Italy. "The results from ELEONOR and OPAL show us that a basal plus strategy is an option for insulin intensification for Type 2 Diabetes insufficiently controlled despite
'/>"/>